Benzoyl peroxide microsphere formulations: What is the science supporting microsphere vehicle technology and clinical use?

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 9, 2009, Pages

  del Rosso, James Q ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; EPIQUIN; FLUOROURACIL; HYDROQUINONE; LIPOSOME; MICROSPHERE; NEOBENZ; RETINOIC ACID; RETINOID; UNCLASSIFIED DRUG;

ACNE; ACNE VULGARIS; ARTICLE; CREAM; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EPIDERMIS; ERYTHEMA; HUMAN; MAINTENANCE THERAPY; MEDICAL PRACTICE; NONHUMAN; PARTICLE SIZE; PRURITUS; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PENETRATION; SKIN SCALING;

EID: 77954294526     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Smith SS, Morhenn V, Webster G. Solid phase porous microspheres: a review. J Drugs Dermatol. 2006;5:969-976.
2. Summary basis of approval: Retin-A Micro 0.1%. www.accessdata.FDA.com. Accessed April 5, 2006.
3. Leyden JJ, Grove JL. Randomized facial tolerability studies comparing gel formulations of retinoids used to treat acne vulgaris. Cutis. 2001;67(suppl): 17-27.
4. Embil K, Nacht S. The microsponge delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13:575-588.
5. Smith EW, Surber C, Tassopoulos T, Maibach HI. Topical dermatological vehicles: a holistic approach. In: Bronaugh RL, Maibach HI, eds. Topical Absorption of Dermatological Products. New York: Marcel Dekker; 2002:457-463.
6. Nyirady J, Nighland M, Payonk G, et al. A comparative evaluation of tretinoin gel microsphere 0.1% versus tretinoin cream 0.025% in reducing facial shine. Cutis. 2000;63:153-156.
7. Saxena S, Nacht S. Polymeric porous delivery systems: polytrap and microsponge. In: Rosen MR, ed. Delivery System Handbook for Personal Care and Cosmetic Products Technology, Applications, and Formulations. Norwich, New York; William Andrew Publishing; 2005:333-350.
8. Nyirady J, Lucas C, Yusuf M, et al. The stability of tretinoin in tretinoin microsphere 0.1%. Cutis. 2002;70:295-298.
9. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clin. 2009;27:17-24.
10. Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis. 2008;82:417-421.
11. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:S1-S38.
12. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007;6:616-622.
13. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized, parallel-group trial. J Drugs Dermatol. 2006;5:256-261.
14. Bikowski J, Del Rosso JQ. Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol. 2008;7:590-595.
15. Data on file. SkinMedica, Carlsbad, California, 2009.
16. Smith SR, Kempers S. A study of 5.5% benzoyl peroxide microsphere cream versus 6% benzoyl peroxide gel in the treatment of acne vulgaris. Cosmet Dermatol. 2006;19:537-542.
17. Del Rosso JQ. What is the role of benzoyl peroxide cleansers in acne management? Do they decrease Propionibacterium acnes counts? Do they reduce acne lesions? J Clin Aesthetic Dermatol. 2008;1:48-51.
18. Del Rosso JQ. Benzoyl peroxide cleansers for the treatment of acne vulgaris: status report on available data. Cutis. 2008;82:336-342.
19. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin. 2009;27:1-15.
20. Gold M. Survey results of compliance, preference, and satisfaction in patients prescribed benzoyl peroxide 8% wash and benzoyl peroxide 9% cleanser for the treatment of acne vulgaris. Poster presented at American Academy of Dermatology Annual Meeting; March 2006; San Francisco, California.
21. Del Rosso JQ, Bikowski JB, Baum E, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007;6:597-600.
22. Del Rosso JQ, Kircik L. Comparison of the tolerability of benzoyl peroxide microsphere cream wash versus gentle cleanser when used in combination with clindamycin and tretinoin gel: a multicenter, investigator-blind, randomized study. Poster presented at: American Academy of Dermatology 67th Annual Meeting, March 6-10, 2009; San Francisco, California.
23. Trookman N, Rizer RL, Ho ET, Ford RO, Mehta RC. Randomized, evaluator-blinded, parallel group comparison study of the tolerability and subject preference of a benzoyl peroxide microsphere wash compared to a gentle non-medicated cleansing wash in mild to moderate acne. Poster presented at: American Academy of Dermatology Summer Meeting, July 30-August 2, 2009; Boston, Massachusetts.